Great presentation about MOA/MOR of ADCs from Pr Massard Christophe Massard. Moving forward w UNLOCK📌

Outstanding comprehensive talk from ⁦ylt⁩ about applications of MRD in GU cancers during the transatlantic exchanges conference between ⁦Dana-Farber⁩ ⁦Gustave Roussy⁩

Bravo Michele Bottosso for this nice review in precision medicine in BC!
Here the link to read it
doi.org/10.1016/j.esmo…

Bravo Jordi Remon ! Congrats!

Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care. Don’t miss the editorial by Drs. Ribeiro, Dixon-Douglas and FabriceAndre that accompanies the latest issue of ESMO Open.
esmoopen.com/article/S2059-…

This editorial calls for a strategic shift in our approach to cancers of unknown primary. FabriceAndre Elie Rassy doi.org/10.1093/oncolo…

#PrecisionMedicine in oncology is evolving towards high-throughput genomics use. This approach may provide vast molecular information in tumors, revealing an average of 4-5 drivers per tumor. Actionable alterations should be prioritized by using validated rankings for treatment…

Thank you very much FabriceAndre and Gustave Roussy for this nice opportunity! A big team effort in collaboration with Unicancer CentraleSupélec

First accomplishment of SUMA, our breast cancer national collaborative group! ESMO - Eur. Oncology Congress 2023 here we go. This is the only way: together 💪🏼💪🏼💪🏼Federico Waisberg Gonzalo Gomez Abuin cristian micheri Diego Lucas Kaen

A stellar panel featuring breast cancer experts Sara Tolaney, @erikahamilton9, and Barbara Pistilli, shedding light on the groundbreaking ADC advancements in breast cancer.
Kudos to Barbara Pistilli for the eloquent discussion of the latest advancements in ADCs
OncoAlert

👀 Great work on clonal hematopoiesis in patients enrolled in phase 1 presented by Julieta Rodriguez 🤩 #ASCO23 from Gustave Roussy
⚠️ 22% prevalence
DMT3A most frequent
Tendency on OS ↗️

« Le Centre national de médecine de précision #PRISM entre dans une nouvelle dimension en devenant un Institut Hospitalo-Universitaire »

📰 Lire le #CommuniquéDePresse ⤵️

gustaveroussy.fr/fr/le-centre-n…

Large study of RNA-seq in pts w refractory metastatic cancer (n=1031). Pan-cancer analyses.

Key msg: high nb of actionable fusions, especially located on PTEN. Certainly a good starting point to evaluate clinical utility of RNA-seq.

science.org/doi/10.1126/sc…

Ayer concluimos el Cursor de Oncología de Precisión de PxMedica y Genotipia con el Workshop interactivo de Comité Molecular de Tumores de Mamá con los expertos Fernanda Mosele Pablo Mando y Pablo Kalfayan! Muchas gracias a todos los asistentes y docentes!

WES & RNAseq landscape of > 1,000 multi-resistant tumors treated Gustave Roussy highlights the current gap in understanding treatment resistances. Preprint medrxiv.org/cgi/content/sh…. Data will be made available upon release in peer-reviewed journal. CentraleSupélec Prism Center.

Congratulations to Julieta Rodriguez and Lauren for their great work presented at #SIOG2022 Gustave Roussy SoFOG on CHIP and the G-CODE use in older patients enrolled in phase I trials 👀👀 Well done 👏🏻👏🏻

#GustaveRoussy dans le top 3 mondial du classement Newsweek 2023 des hôpitaux en #cancérologie ! Ce classement vient saluer notre engagement en termes de recherche clinique et d’innovations pour améliorer la vie des #patients touchés par un #cancer

newsweek.com/rankings/world…

Now on line right after the historic FDA approval of T-DXd for HER2low MBC: Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer - ScienceDirect sciencedirect.com/science/articl… OncoAlert